SCHEMBL10179276

SCHEMBL10179276

N#Cc1ccc(C(=O)Nc2ccc(-c3ccc4ncc(N5CCN(Cc6cccnc6)CC5)nc4c3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.55
EPAS1 Q99814 5/20 0.55
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PRKAA2 P54646 1/20 0.46
HTR2C P28335 4/20 0.45
MCHR1 Q99705 4/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
MLLT1 Q03111 1/20 0.44
ABCB1 P08183 1/20 0.44
CYP3A4 P08684 1/20 0.44
SLC2A1 P11166 1/20 0.43
ABL1 P00519 1/20 0.43
PDGFRB P09619 1/20 0.43
BCR P11274 1/20 0.43
PDGFRA P16234 1/20 0.43
PRKCA P17252 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10179300 0.93 SLC2A1 (0.53) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL1442483 0.91 MAPT (0.58) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL10179384 0.91 HIF1A (0.55) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL13276315 0.90 HIF1A (0.45) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL1441991 0.90 HIF1A (0.53) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL12811966 0.90 HIF1A (0.53) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL1442629 0.90 HIF1A (0.55) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL10179606 0.90 SMN1; SMN2 (0.59) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL10179566 0.89 HIF1A (0.67) HIF1AEPAS1MAPTMAPK1SMN1; SMN2
SCHEMBL10180943 0.88 MAPT (0.53) HIF1AEPAS1MAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 US claimed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 US claimed
EP-2473498-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2012-07-11 EP claimed
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 US disclosed
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 US disclosed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 US disclosed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS ABL1, TYK2, JAK2 HIF1A 2989/4885EPAS1 1421/4885MAPT 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.